Beam Therapeutics Inc.

NASDAQ:BEAM

Biotechnology

Healthcare
$21.01 +1.46%

+$0.48 today

Market cap
$2.17B
Beta
2.20
P/E (TTM)
-52.3
EPS (TTM)
-$0.63
52W Low $15.60High $36.44

Volume 4.86M

Average 2.11M

BEAM Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Beam Therapeutics Inc.NASDAQ: BEAM

Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026

Stock-based compensation declines year over year

Q2 FY2026 stock-based compensation of $19.28M fell 20.9% year over year, ahead of the -111.5% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 1.2% from the prior quarter. Over 3 fiscal years it compounded at +3.8% a year.

Context

  • Stock-based compensation amounted to 67.4% of revenue in FY2025, down 122.5 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -20.9% holds above the trailing-twelve-month pace of -111.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$19.28M+1.2% QoQ
Last fiscal yearDec 2025
$94.24M-21.9% YoY
LTMJun 2026
-$12.73M-111.5% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-20.9%——
1 year-21.9%——
3-year CAGR+3.8%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
94.24M USD
Year-over-year change
-21.9%
4-year CAGR
+21.3%

Stock-Based Compensation vs competitors

How BEAM compares with its peers on the latest reported figures

  • BEAM's LTM Jun 2026 stock-based compensation of $12.73M is the 5th largest of the 9 companies compared; the peer median is $16.31M.
  • Its year-over-year change of -111.5% is the lowest of 9, against a peer median of -34.0%.
  • Stock-based compensation amounts to 8.2% of revenue for BEAM, versus a peer median of 99.6%.
BEAM Competitors Peer median
Stock-Based Compensation for BEAM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$145.91M +2.8%+19.1%220.8%
CRSPCRISPR Therapeutics AGLTM Sep 2026$69.68M -8.8%-9.5%276.8%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$33.74M -35.1%-23.4%—
FATEFate Therapeutics, Inc.LTM Mar 2026$21.47M -43.3%-31.8%340.0%
BEAMBeam Therapeutics Inc.LTM Jun 2026$12.73M -111.5%+3.8%8.2%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$11.16M -32.8%+2.7%99.6%
EDITEditas Medicine, Inc.LTM Mar 2026$9.12M -45.7%-30.1%23.6%
DTILPrecision BioSciences, Inc.LTM Mar 2026$8.91M -28.8%-19.0%19.8%
CLLSCellectis S.A.LTM Mar 2026$1.28M -60.6%—1.9%
Peer median (excluding BEAM) $16.31M-34.0%-19.0%99.6%

Competitors are the stored peer set for BEAM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(370.64M)(289.09M)(132.53M)(376.74M)(79.99M)
Depreciation & Amortization7.45M14.15M20.01M21.93M22.29M
Deferred Income Tax00000
Stock-Based Compensation43.57M84.32M98.65M120.66M94.24M
Change in Working Capital111.25M251.63M(116.46M)(110.22M)(131.02M)
Accounts Receivables(300M)300M000
Inventory0(300M)000
Accounts Payables818K2.37M(7.58M)1.81M6.04M
Other Working Capital410.44M249.26M(108.88M)(112.03M)(137.06M)
Other Non-Cash Items142.1M(38.48M)(18.87M)(2.87M)(250.63M)
Operating Cash Flow(66.27M)22.53M(149.2M)(347.25M)(345.1M)
Capital Expenditures(46.81M)(48.95M)(33.73M)(8.95M)(14.95M)
Acquisitions (Net)620K412.39M00(78K)
Purchases of Investments(777.22M)(1.62B)(984.34M)(486.44M)(1.21B)
Sales of Investments529.27M1.2B1.09B680.39M848.63M
Other Investing Activities0(412.39M)00254.75M
Investing Cash Flow(294.14M)(461.34M)71.84M185.01M(121.44M)
Debt Repayment(2.12M)(2.29M)(2.25M)(485K)0
Common Stock Issued757.45M108.26M270.17M8.22M478.05M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities810K5.62M8.53M00
Financing Cash Flow756.14M111.59M276.45M7.74M478.05M
Effect of Forex Changes00000
Net Change in Cash395.73M(327.22M)199.09M(154.5M)11.51M
Free Cash Flow(113.08M)(26.42M)(182.93M)(356.19M)(360.05M)

Beam Therapeutics Inc.

NASDAQ:BEAM

Intrinsic Alpha fair value

Locked

Current Price

$21.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.